Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy

NCT01941316 is registered in ClinicalTrials.gov with Cancer Research and Biostatistics Clinical Trials Consortium as lead sponsor.

NCT NCT01941316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01941316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy
Lead sponsor
Cancer Research and Biostatistics Clinical Trials Consortium
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2013
Completion date
July 1, 2019
Enrollment
78 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

irinotecan sensitive cancers, non small cell lung carcinoma, small cell lung carcinoma